
    
      Upon determination of eligibility, patients will receive:

        -  Ifosfamide + Carboplatin + Etoposide + Rituximab

      Patients showing no response to this combination regimen will receive 90Y Zevalin after two
      cycles or when progression is clearly documented. In responding patients, four cycles will be
      administered, followed by 90Y Zevalin.
    
  